MedPath

DaxibotulinumtoxinA

Generic Name
DaxibotulinumtoxinA
Brand Names
Botox, Botox Cosmetic, Daxxify, Dysport, Xeomin
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
E211KPY694
Background

DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.

DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. DAXI or DAXXIFY, a product of daxibotulinumtoxinA, incorporates RTP004, a proprietary synthetic stabilizing peptide for enhanced product stability.

Indication

DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. It is also used for the treatment of cervical dystonia in adult patients.

Associated Conditions
Cervical Dystonia, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL)
Associated Therapies
-
2minutemedicine.com
·

2 Minute Medicine Rewind October 7, 2024

Predicting dementia in primary care for 60-79 year olds should include age, history of stroke or epilepsy, gait problems, anticholinergic burden, use of SSRIs, receipt of social services, third-party involvement in consultations, and high missed primary care appointments. For 80-89 year olds, similar factors apply but with weaker associations. S100β levels 24 hours post-IVT are independently associated with hemorrhagic transformation, infarct volume, and prognosis in stroke patients. DaxibotulinumtoxinA-lanm 500U showed the greatest reduction in MAS scores in patients with spasticity following stroke or traumatic brain injury. Double-dose ESWT to the gastrocnemius and soleus showed greater improvements in post-stroke ankle plantar flexor spasticity. Just-in-time adherence support systems in gamified cognitive training should be applied based on key performance indicators like highest level achieved, total game sessions played, and overall gameplay proportion.
businesskorea.co.kr
·

Hugel Accelerates Global Expansion of Botulinum Toxin 'Letybo'

Hugel's Letybo, a botulinum toxin product, received FDA approval, making it the second Korean company to enter the U.S. market. Expected annual sales and operating profit for Hugel are 377.2 billion won and 153.7 billion won, respectively, with a 58% overseas sales ratio. Letybo is now available in 64 countries, with significant growth in China and recent launch in Indonesia. Hugel faces a final ruling on a trade secret infringement lawsuit with Medytox on Oct. 10.
thebambooworks.com
·

Suhuan Pharma stock skyrockets on latest share buyback program

Sihuan Pharmaceutical Holdings Group Ltd. announced a new program to buy back up to HK$500 million of its shares over 12 months, supported by a strong portfolio of innovative drugs and diabetes biosimilars. The company, originally focused on cardiovascular and oncology generic drugs, expanded into medical aesthetics in 2021. Despite a 10% revenue drop in H1 2024, medical aesthetics revenue surged 66.4%. Shares surged 23.6% to a 52-week high.
koreabiomed.com
·

Galderma Korea appoints Lee Jai-hyuck as new GM < Pharma

Galderma Korea appoints Lee Jai-hyuck, former aesthetics business unit director, as new GM. Lee, with over 25 years in global pharmaceutical and aesthetics industries, succeeds Kim Youn-hee. He led successful product launches and brand renewals, enhancing the company's portfolio and growth.
theglobeandmail.com
·

3 Magnificent Dividend Stocks to Buy in October

Motley Fool contributors recommend AbbVie, Amgen, and Pfizer as top dividend stocks for October, highlighting their strong dividend histories, yields, and business strengths.
thedailybeast.com
·

The Best New Launches From Heat Healer, Tecovas, Nars and More

New Kids on the Block highlights September's best product launches, including SkinMedica's HA⁵ Hydra Collagen Replenish + Restore Hydrator, Garage Clothing's loungewear, Caliray's Blurry Blush, Tecovas' Dakota boots, Nars' Explicit Lipstick, Quince's cashmere sweaters, Beachwaver's Heatless Curl Kit, Heat Healer's lymphatic leggings, and Typology Paris' Fortifying Brow Gel.
statnews.com
·

Dockworker strike puts drug supplies at risk

ResMed sees GLP-1 drugs boosting CPAP sales; Ron Renaud returns to biotech with Kailera Therapeutics; Gilead licenses lenacapavir for generic production in low-income countries; Senators urge FTC to investigate PBMs over private-label deals; dockworker strike threatens GLP-1 drug supplies; Hurricane Helene impacts Baxter's supply network.
indiamedtoday.com
·

Hair and skin science solution provider QR678 appoints Sridhar Ranganathan

QR678 appoints medtech leader Sridhar Ranganathan to advisory board, leveraging his expertise in biotechnology, healthcare, and aesthetics to bolster strategic direction and market penetration.
stocktitan.net
·

AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting

AEON Biopharma announced positive FDA Biosimilar Advisory Meeting outcome for ABP-450 as a BOTOX® biosimilar, aligning on the 351(k) regulatory pathway. Comparative analytical studies start Q4 2024, with a BPD Type 2 meeting planned for 2025. AEON aims to bring prabotulinumtoxinA to the U.S. market for all BOTOX's approved and future therapeutic indications under a single approval, anticipating a Phase 3 program to compare ABP-450 with BOTOX®.
biospectrumindia.com
·

QR678 appoints industry veteran and medtech leader Sridhar Ranganathan to advisory board

QR678 appoints Sridhar Ranganathan to its Board of Advisors, leveraging his expertise in biotechnology, healthcare, and aesthetics from his tenure at Allergan, where he scaled up Botox and transformed it into a leading product.
© Copyright 2025. All Rights Reserved by MedPath